United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062 AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development… bypharmanewsdailyJuly 27, 2020
